• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

心肌存活性试验

Myocardial viability on trial.

作者信息

Bolognese Leonardo, Reccia Matteo Rocco

机构信息

Cardiovascular Department, Azienda Ospedaliera Toscana Sudest.

出版信息

Eur Heart J Suppl. 2024 Apr 17;26(Suppl 1):i15-i18. doi: 10.1093/eurheartjsupp/suae005. eCollection 2024 Apr.

DOI:10.1093/eurheartjsupp/suae005
PMID:38867871
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11167980/
Abstract

The concept of myocardial viability is usually referred to areas of the myocardium, which show contractile dysfunction at rest and in which contractility is expected to improve after revascularization. The traditional paradigm states that an improvement in function after revascularization leads to improved health outcomes and that assessment of myocardial viability in patients with ischaemic left ventricular dysfunction (ILVD) is a prerequisite for clinical decisions regarding treatment. A range of retrospective observational studies supported this 'viability hypothesis'. However, data from prospective trials have diverged from earlier retrospective studies and challenge this hypothesis. Traditional binary viability assessment may oversimplify ILVD's complexity and the nuances of revascularization benefits. A conceptual shift from the traditional paradigm centred on the assessment of viability as a dichotomous variable to a more comprehensive approach encompassing a thorough understanding of ILVD's complex pathophysiology and the salutary effect of revascularization in the prevention of myocardial infarction and ventricular arrhythmias is required.

摘要

心肌存活的概念通常指心肌区域,这些区域在静息时表现出收缩功能障碍,并且预计在血运重建后收缩性会改善。传统观念认为,血运重建后功能的改善会带来更好的健康结局,并且对缺血性左心室功能障碍(ILVD)患者进行心肌存活评估是治疗临床决策的先决条件。一系列回顾性观察性研究支持了这一“存活假设”。然而,前瞻性试验的数据与早期回顾性研究有所不同,并对这一假设提出了挑战。传统的二元存活评估可能会过度简化ILVD的复杂性以及血运重建益处的细微差别。需要从以将存活评估作为二分变量为中心的传统模式,转变为一种更全面的方法,该方法要全面理解ILVD复杂的病理生理学以及血运重建在预防心肌梗死和室性心律失常方面的有益作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce00/11167980/80ac1ca5b25f/suae005f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce00/11167980/80ac1ca5b25f/suae005f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ce00/11167980/80ac1ca5b25f/suae005f1.jpg

相似文献

1
Myocardial viability on trial.心肌存活性试验
Eur Heart J Suppl. 2024 Apr 17;26(Suppl 1):i15-i18. doi: 10.1093/eurheartjsupp/suae005. eCollection 2024 Apr.
2
The Evolving Paradigm of Revascularization in Ischemic Cardiomyopathy: from Recovery of Systolic Function to Protection Against Future Ischemic Events.缺血性心肌病血运重建治疗模式的演变:从收缩功能恢复到预防未来缺血事件。
Curr Cardiol Rep. 2023 Nov;25(11):1513-1521. doi: 10.1007/s11886-023-01977-5. Epub 2023 Oct 24.
3
[Myocardial viability: when and how to look for it, its prognostic impact and interaction with benefits of revascularization].[心肌存活:何时以及如何寻找心肌存活,其预后影响以及与血运重建益处的相互作用]
G Ital Cardiol (Rome). 2024 Jul;25(7):475-482. doi: 10.1714/4282.42634.
4
Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.用于评估心肌活力的正电子发射断层扫描:一项基于证据的分析。
Ont Health Technol Assess Ser. 2005;5(16):1-167. Epub 2005 Oct 1.
5
Positron emission tomography for the assessment of myocardial viability: an evidence-based analysis.用于评估心肌活力的正电子发射断层扫描:基于证据的分析。
Ont Health Technol Assess Ser. 2010;10(16):1-80. Epub 2010 Jul 1.
6
Magnetic resonance imaging (MRI) for the assessment of myocardial viability: an evidence-based analysis.用于评估心肌存活性的磁共振成像(MRI):一项基于证据的分析。
Ont Health Technol Assess Ser. 2010;10(15):1-45. Epub 2010 Jul 1.
7
Myocardial viability in ischemic heart disease: new directions and perspectives.缺血性心脏病中的心肌存活:新方向与展望。
Ital Heart J. 2001 Feb;2(2):93-9.
8
[Reversible dysfunction of the left ventricle in coronary disease (part two): hibernation and methods for detection of viability].[冠心病中左心室的可逆性功能障碍(第二部分):心肌冬眠及存活心肌检测方法]
Med Pregl. 2000 Mar-Apr;53(3-4):146-53.
9
Myocardial viability testing: all STICHed up, or about to be REVIVED?心肌活力检测:全都“缝合”好了,还是即将“复苏”?
Eur Heart J. 2022 Jan 13;43(2):118-126. doi: 10.1093/eurheartj/ehab729.
10
Is viability still viable after the STICH trial?STICH 试验后,是否仍可行活组织检查?
Eur Heart J Cardiovasc Imaging. 2012 Mar;13(3):219-26. doi: 10.1093/ejechocard/jer237. Epub 2011 Nov 11.

本文引用的文献

1
Viability and Outcomes With Revascularization or Medical Therapy in Ischemic Ventricular Dysfunction: A Prespecified Secondary Analysis of the REVIVED-BCIS2 Trial.缺血性心室功能障碍患者血运重建或药物治疗的存活率和结局:REVIVED-BCIS2 试验的预先设定的二次分析。
JAMA Cardiol. 2023 Dec 1;8(12):1154-1161. doi: 10.1001/jamacardio.2023.3803.
2
Assessment of Myocardial Viability in Ischemic Cardiomyopathy-Scarred by the Data but Still Alive.缺血性心肌病中心肌存活的评估——虽被数据所“瘢痕化”但仍具活力
JAMA Cardiol. 2023 Dec 1;8(12):1161-1163. doi: 10.1001/jamacardio.2023.3846.
3
STICH3C: Rationale and Study Protocol.
STICH3C:研究原理和方案。
Circ Cardiovasc Interv. 2023 Aug;16(8):e012527. doi: 10.1161/CIRCINTERVENTIONS.122.012527. Epub 2023 Aug 15.
4
Revascularization in ischaemic cardiomyopathy: how to interpret current evidence.缺血性心肌病的血运重建:如何解读当前证据。
Eur Heart J. 2023 Feb 1;44(5):365-367. doi: 10.1093/eurheartj/ehac794.
5
Do Patients With Non-Viable Myocardium From Ischemic Cardiomyopathy Benefit From Revascularization? A Systematic Review And Meta-Analysis.缺血性心肌病无存活心肌患者是否从血运重建中获益?系统评价和荟萃分析。
Cardiovasc Revasc Med. 2023 Feb;47:27-32. doi: 10.1016/j.carrev.2022.08.032. Epub 2022 Aug 28.
6
Myocardial viability testing: all STICHed up, or about to be REVIVED?心肌活力检测:全都“缝合”好了,还是即将“复苏”?
Eur Heart J. 2022 Jan 13;43(2):118-126. doi: 10.1093/eurheartj/ehab729.
7
Myocardial Viability Assessment Before Surgical Revascularization in Ischemic Cardiomyopathy: JACC Review Topic of the Week.心肌梗死后心肌活力评估:缺血性心肌病患者的外科血运重建。
J Am Coll Cardiol. 2021 Sep 7;78(10):1068-1077. doi: 10.1016/j.jacc.2021.07.004.
8
Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).经冠状动脉旁路移植术或经皮冠状动脉介入治疗的缺血性心力衰竭患者的长期死亡率:来自瑞典冠状动脉造影和血管成形术登记处(SCAAR)的见解。
Eur Heart J. 2021 Jul 15;42(27):2657-2664. doi: 10.1093/eurheartj/ehab273.
9
Myocardial Viability and Long-Term Outcomes in Ischemic Cardiomyopathy.心肌活力与缺血性心肌病的长期预后
N Engl J Med. 2019 Aug 22;381(8):739-748. doi: 10.1056/NEJMoa1807365.
10
The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results.STICH 试验(缺血性心力衰竭的手术治疗):死亡模式结果。
JACC Heart Fail. 2013 Oct;1(5):400-8. doi: 10.1016/j.jchf.2013.04.012. Epub 2013 Sep 11.